Inclusion Criteria:

          -  Expected survival > 12 weeks

          -  Diagnosis of Multiple Myeloma by IMWG updated criteria (2014)

          -  Pathology demonstrated that BCMA-poitive malignant plasma cells exited in bone marrow
             or plamacytoma

          -  Exited measurable lesions and in accordance with one of the following test indicators:
             serum M protein≥1 g/dl; urine M protein≥200 mg/24h; serum free light chain≥10 mg/dl;
             diagnosis of plasmacytoma by biopsy

          -  The criteria for relapsed and refractory multiple myeloma: patients previously
             received at least 3 different prior treatment regimens for multiple myeloma, including
             protein inhibitors (eg: Bortezomib), and immunomodulator (eg: Revlimid), and have
             disease progression in the past 60 days

          -  At least 90 days after stem cell transplantation

          -  Clinical performance status of ECOG score 0-2

          -  Creatinine≤2.0 mg/dl

          -  Bilirubin≤2.0 mg/dl

          -  The ALT/AST value is lower than 2.5-fold of normal value

          -  Accessible to intravenous injection, and no white blood cell collection
             contraindications

          -  Sexually active patients must be willing to utilize one of the more effective birth
             control methods for 30 days after the CTL infusion. Male partner should use a condom

          -  5mg/day dose of Prednisone or other equivalent steroid hormone drugs (eg:
             Dexamethasone) were not used for two weeks before apheresis and CAR-T infusion

          -  Able to understand and sign the Informed Consent Document.

        Exclusion Criteria:

          -  Patients with symptoms of central nervous system

          -  Patients with second malignancies in addition to multiple myeloma

          -  Active hepatitis B or C, HIV infections

          -  Any other active diseases could affect the enrollment of this trial

          -  Long term use of immunosuppressive agents after organ transplantation, except
             currently receiving or recently received glucocorticoid treatment

          -  Patients with organ failure

          -  Women of child-bearing potential who are pregnant or breastfeeding during therapy, or
             have a planned pregnancy with 2 months after therapy

          -  A history of mental illness and poorly controlled

          -  Women of child-bearing potential who are not willing to practice birth control from
             the time of enrollment on this study and for 2 months after receiving the preparative
             regimen. Women of child bearing potential must have a negative serum or urine
             pregnancy test performed within 48 hours before infusion

          -  Patients who are accounted by researchers to be not appropriate for this test

          -  Subjects suffering disease affects the understanding of informed consent or complying
             with study protocol